See more : PT Allo Bank Indonesia Tbk (BBHI.JK) Income Statement Analysis – Financial Results
Complete financial analysis of TC Biopharm (Holdings) Plc (TCBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TC Biopharm (Holdings) Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ayurcann Holdings Corp. (AYURF) Income Statement Analysis – Financial Results
- Burckhardt Compression Holding AG (0QNN.L) Income Statement Analysis – Financial Results
- Point Loma Resources Ltd. (FMTNF) Income Statement Analysis – Financial Results
- Taiho Kogyo Co., Ltd. (6470.T) Income Statement Analysis – Financial Results
- GateKeeper USA, Inc. (GTKP) Income Statement Analysis – Financial Results
TC Biopharm (Holdings) Plc (TCBP)
About TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.77M | 7.59M | 6.16M | 6.68M | 8.61M |
| General & Administrative | 6.47M | 8.34M | 3.11M | 2.21M | 3.01M |
| Selling & Marketing | 402.31K | 402.31K | 0.00 | 0.00 | 0.00 |
| SG&A | 6.87M | 8.74M | 3.11M | 2.21M | 3.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Cost & Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Interest Income | 83.03K | 6.75M | 3.44M | 291.03K | 253.51K |
| Interest Expense | 0.00 | 6.75M | 3.44M | 292.06K | 275.41K |
| Depreciation & Amortization | 630.06K | 762.47K | 811.96K | 878.64K | 721.93K |
| EBITDA | -13.61M | -11.32M | -6.48M | -5.26M | -5.92M |
| EBITDA Ratio | 0.00% | -294.48% | -327.25% | -303.65% | -172.71% |
| Operating Income | -14.24M | -12.08M | -7.29M | -6.89M | -6.64M |
| Operating Income Ratio | 0.00% | -314.32% | -368.28% | -348.05% | -193.78% |
| Total Other Income/Expenses | 7.24M | 9.05M | -7.70M | -291.03K | -253.51K |
| Income Before Tax | -7.00M | -3.03M | -14.98M | -6.63M | -6.89M |
| Income Before Tax Ratio | 0.00% | -78.91% | -757.25% | -335.07% | -201.18% |
| Income Tax Expense | -1.09M | 1.72M | 1.41M | 1.17M | 826.07K |
| Net Income | -5.91M | -1.31M | -13.58M | -5.46M | -6.07M |
| Net Income Ratio | 0.00% | -34.17% | -686.12% | -275.84% | -177.07% |
| EPS | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| EPS Diluted | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| Weighted Avg Shares Out | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
| Weighted Avg Shares Out (Dil) | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia
5 patients treated in "safety cohort" showed no drug related Serious Adverse Events Restart of trial after amendment approved by MHRA to increase dose level EDINBURGH, Scotland , July 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or...
TCBP Announces Launch of Compassionate Use Program for TCB008
The Company's lead therapeutic will be available through a newly opened compassionate use program EDINBURGH, Scotland , May 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta...
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive...
Why Is TC Biopharm (TCBP) Stock Up 51% Today?
TC BioPharm (NASDAQ: TCBP ) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a major deal to acquire another company. According to a press release from TC BioPharm, it intends to acquire a private biotechnology company...
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage...
Why Is TC Biopharm (TCBP) Stock Up 78% Today?
TC BioPharm (NASDAQ: TCBP ) stock is heading higher on Thursday after the company announced an acquisition that would beef up its therapeutic platform. According to a news report, TC BioPharm has executed a non-binding letter of intent for the...
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
EDINBURGH, Scotland , April 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of...
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
Developing streamlined approach to reduce cost per patient by 85% EDINBURGH, Scotland , April 2, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies...
TCBP Adjourns General Meeting Until a Later Date
EDINBURGH, Scotland , March 19, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has...
TCBP Announces Exercise of Series D Warrants For Cash
• Company receives gross proceeds of $1.26 M from transaction EDINBURGH, Scotland , March 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies...
Source: https://incomestatements.info
Category: Stock Reports